Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

U.S. health officials have told more than a half-dozen of the nation’s top medical organizations that they will no longer ...